These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 16634234)
1. Adverse drug reaction reporting and pharmacovigilance of new therapeutic agents. Haas SJ South Med J; 2006 Apr; 99(4):325-6. PubMed ID: 16634234 [No Abstract] [Full Text] [Related]
2. New anticonvulsants--new adverse effects. Tebb Z; Tobias JD South Med J; 2006 Apr; 99(4):375-9. PubMed ID: 16634247 [TBL] [Abstract][Full Text] [Related]
3. Emergent complications of the newer anticonvulsants. Wade JF; Dang CV; Nelson L; Wasserberger J J Emerg Med; 2010 Feb; 38(2):231-7. PubMed ID: 18762404 [TBL] [Abstract][Full Text] [Related]
4. DRESS: is oxcarbazepine safer than carbamazepine? An analysis of the French Pharmacovigilance database. Le Louët H; Thomas L; Babai S Eur J Neurol; 2008 May; 15(5):e43. PubMed ID: 18355308 [No Abstract] [Full Text] [Related]
5. [Experience with eslicarbazepine in patients with hiponatremia due to carbamazepine and oxcarbacepine]. Bermejo PE; Dorado R; Belarrinaga B Rev Neurol; 2015 Jul; 61(1):47-8. PubMed ID: 26108910 [No Abstract] [Full Text] [Related]
6. Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy. Ryan M; Adams AG; Larive LL Am J Health Syst Pharm; 2001 Sep; 58(17):1637-9. PubMed ID: 11556658 [TBL] [Abstract][Full Text] [Related]
8. Care required when prescribing carbamazepine. Zakrzewska JM Br Dent J; 1998 Nov; 185(10):500-1. PubMed ID: 9874875 [No Abstract] [Full Text] [Related]
9. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance. Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946 [No Abstract] [Full Text] [Related]
11. [Symptomatic hyponatremia induced by oxcarbazepine]. Miranda M; Castillo JL; Passig C Rev Med Chil; 2003 Feb; 131(2):225-6. PubMed ID: 12708264 [No Abstract] [Full Text] [Related]
12. [Severe hyponatremia by oxcarbazepine in an elderly]. Valentini S; Arbaizar-Rodríguez P; Abarca-Costalago M; Valdivielso-Felices P; González-Santos P Rev Neurol; 2009 Jun 1-15; 48(11):614-5. PubMed ID: 19472164 [No Abstract] [Full Text] [Related]
13. Topiramate and metabolic acidosis: a case series and review of the literature. Groeper K; McCann ME Paediatr Anaesth; 2005 Feb; 15(2):167-70. PubMed ID: 15675937 [TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance and use of online health information. Masoni M; Guelfi MR; Conti A; Gensini GF Trends Pharmacol Sci; 2013 Jul; 34(7):357-8. PubMed ID: 23759353 [No Abstract] [Full Text] [Related]
15. A case of type IV hypersensitivity to topiramate and carbamazepine. Schiavino D; Nucera E; Buonomo A; Musumeci S; Pollastrini E; Roncallo C; Lombardo C; Alonzi C; Pecora V; Corradini C; De Pasquale T; Patriarca G Contact Dermatitis; 2005 Mar; 52(3):161-2. PubMed ID: 15811034 [No Abstract] [Full Text] [Related]
18. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use. Hauben M; Reich L Eur J Clin Pharmacol; 2005 Jul; 61(5-6):479-80. PubMed ID: 15991039 [No Abstract] [Full Text] [Related]
19. Hyponatremia from oxcarbazepine and carbamazepine. Dong X; Leppik IE; White J; Rarick J Neurology; 2005 Dec; 65(12):1976-8. PubMed ID: 16380624 [TBL] [Abstract][Full Text] [Related]